Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 32 | ECE2013 | Next issue

15th European Congress of Endocrinology

ea0032oc3.1 | Thyroid | ECE2013

Targeting of PATZ1 by miR-29b is a downstream effect of oncogenic Ras signalling in thyroid cells

Vitiello Michela , Valentino Teresa , De Menna Marta , Serpico Luigia , Mansueto Sonia , Vita Gabriella De , Fusco Alfredo , Fedele Monica

PATZ1, a member of the POZ-ZF protein family of transcription factors is emerging as an important cancer-associated factor that can act either as oncogene or tumour-suppressor depending on the cellular context. Consistent with a tumour-suppressor role in thyroid cells, we have shown that PATZ1 is highly downregulated in anaplastic thyroid carcinomas compared to normal thyroid tissue and is a powerful inhibitor of anaplastic thyroid cancer cell survival, migration, invasiveness...

ea0032oc3.2 | Thyroid | ECE2013

Mitochondrial mass and function is regulated by PI3K signaling in thyroid cancer cells

Iwen K Alexander , Schroder Erich , Resch Julia , Lindner Ulrich , Konig Peter , Lehnert Hendrik , Perwitz Nina , Ibrahim Saleh , Brabant Georg

Objective: Abnormal mitochondria are well known in oxyphilic thyroid tumors but recent data also confirm profound mitochondrial alterations in other thyroid carcinomas. These changes are linked to the aggressiveness of the tumors. Our group recently demonstrated in an in vivo model, that inhibition of phosphoinositide 3-kinase (PI3K) signalling suppressed the invasive and metastatic behaviour of thyroid cancer cells. Here, we evaluated whether a modulation of PI3K sig...

ea0032oc3.3 | Thyroid | ECE2013

ESE Young Investigator Award

Grassi Elisa Stellaria , Vezzoli Valeria , Negri Irene , Persani Luca

Poorly differentiated thyroid cancers are associated with variable types of p53 function derangements and bad prognosis due to the lack of effective treatments. SP600125 is a widely used JNK-inhibitor which recently showed anticancer properties in a p53 related way. Here, we tested the effect of SP600125 on four different thyroid cancer cell lines derived from PDTCs and ATCs with different p53 status.We analyzed the effects on cellular replication and ap...

ea0032oc3.4 | Thyroid | ECE2013

DNA methylation signatures identify biologically distinct thyroid cancer subtypes

Fernandez-Morera Juan Luis , Rodriguez-Rodero Sandra , Alvarez Elias Delgado , Fernandez-Fernandez Agustin , Fernandez-Vega Ivan , Gonzalez-Marquez Rocio , Sanchez-Rivas Veronica , Suarez-Gutierrez Lorena , Rodriguez Caballero Maria Galiana , Blanco Jessica Ares , Fernandez-Fraga Mario , Menendez-Torre Edelmiro

Introduction: The global patterns of aberrant DNA methylation in thyroid cancer are not known. In this study, we have used DNA methylation arrays to determine, for the first time, the genome-wide promoter methylation status of different subtypes of thyroid tumors.Material and methods: We analyzed a cohort of 54 snap frozen thyroid samples (thirteen papillary tumors, six follicular, eleven anaplastic, twenty medullar and four normal tissue samples). Also ...

ea0032oc3.5 | Thyroid | ECE2013

Role of the calcium-calmodulin dependent kinase 2 in medullary thyroid carcinoma

Russo Eleonora , Salzano Marcella , De Falco Valentina , Santoro Massimo , Mian Caterina , Barollo Susi , Vitale Mario

Recent studies demonstrated that the calcium/calmodulin dependent kinase 2 (CaMKII) is involved in the regulation of proliferation and survival of epithelial cells, were it phosphorylates RAF-1 and modulates MAPK pathway. A endogenous CaMKII inhibitor (hCaKIINα) is expressed in some cell types. It is down-expressed in colon and in ovarian cancer where it inversely correlates with the disease extension.Aim of our study is to determine the possible ro...

ea0032oc3.6 | Thyroid | ECE2013

Subclinical hyperthyroidism and risk of cardiovascular and all-cause mortality

Selmer Christian , Olesen Jonas , Madsen Jesper , Faber Jens , Hansen Peter , Pedersen Ole , Hansen Morten , Torp-Pedersen Christian , Gislason Gunnar

ESE Young Investigator AwardBackground: It is still discussed if subclinical hyperthyroidism and ‘high-normal’ thyroid function are risk-factors for cardiovascular mortality.Objectives: To examine the risk of cardiovascular and all-cause mortality in relation to subclinical hyperthyroidism.Methods: Patients consulting their general practitioner from 2000 to 2009 in Copenhagen, Denmark, who ...